Member Info for Reckoner

This is a serious statement of what the government are putting their/our money on.
Diagnostics to get us out of this healthcare vs economy nightmare.
And the tender is worded to take account of the leading edge nature of some of these products, the inevitable introduction of new versions without needing to submit for reapproval and the relatively small size of many of the suppliers. Whatsmore, it’s for two years.
This is an open door for those with high quality products.

How about reporting this on the CNCT board? Someone there might know a bit more.

I've been using this site for info on worldwide tests: https://chs.asu.edu/diagnostics-commons/testing-commons

If you filter appropriately, it says there are 48 tests (available or under development) using saliva.
Of these 11 are targeting viral antigen.
5 of these require complex lab analysis, so unlikely to be relevant to rapid testing.
One from Roche can be used for Point of Care testing.
Leaving 5 tests which are for self-analysis, i.e. most suitable for home use and rapid results.
Of these one is an ELISA test from an Israeli company.
Leaving 4 which are Lateral Flow Tests.
2 of these are US-based and still under development (3M & Orasure).
One is from University of Lille in France, so unlikely for commercial ramp-up to supply UK.
The other one is Avacta.
But I think this site might be missing a trick on Mologic which it lists as requiring complex lab analysis. Mologic are certainly developing a rapid antigen test which has been trialled at Heathrow airport and which I assume required a mobile lab.
But my understanding was that Mologic are developing a rapid LFA for home use (self-analysis).

Given that many companies must be seeking to develop these tests, the website I've been using might not be keeping up with things.

Sharesurfer - what about the ones who hold both? Like me.

Thanks Safy.
And for the extra info about Mologic - I thought I’d seen something about a double test but couldn’t recall where.

Safy,
I find these debates help to clarify why I'm invested and challenge my assumptions about the risks I'm taking. It's actually a really useful way of generating some facts I didn't know before. So no problem with passionate, rational arguments. I just don't like the territorial stuff - and this goes for the AVCT folk too - as I think it deters other investors from posting their thoughts, which might also be useful. Someone who defends another company or tries to put an argument forward that doesn't seem to fit with that BB shouldn't always be dismissed as a troll.

'have you started the 4 month tech transfer to abi?'

Safy, which "me" are you referring to? The one who owns AVCT or the one who owns ODX?
Like quite a few folk, I own both and I'm more interested in objective facts than all this playground yah-boo stuff.

‘Also BBI capacity isn’t huge, one of the links above states they’ll ramp up to millions a month. We are going to ramp up to millions too. And if bbi are the ONLY partner which I think they are. For the most in demand test in the world having a capacity which is in the hundreds of thousands right now..... I rest my case there my friend.

Avacta should have a queue X miles long for manufacturers wanting their test. Except they don’t and they’ve signed up to bbi who’s own capacity isn’t exactly huge. What does that tell you?’

Safy, Avacta have signed up Abingdon Health as a manufacturing partner: https://avacta.com/avacta-expands-rapid-sars-cov-2-antigen-test-manufacturing-capacity/

monkey, the China tests under the company names Innova and Healgen have been through the official testing route: https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/lateral-flow-devices-results

But these don’t appear to be competing with Avacta on the LFT side.
Are you aware of any others from China which the government have procured? It’s difficult to follow it all.

So if we end up with mass self-testing at home, I can't see many contenders here. I suspect most of these companies are simply convenient at this point for proving the concept where process issues are flushed out. Also helps to gain an idea of what challenges will be presented by the public to using these tests.

The non-avct tests listed here are ones where the result is analysed by a professional, either in a lab or at the point of care. Also some are nose swabs. At least according to the testing commons site:
https://chs.asu.edu/diagnostics-commons/testing-commons
Don’t know how up to date or accurate this site is as I think Mologic is self-analysed and doesn’t require a healthcare professional. But the gist is there are very few lateral flow antigen tests for full self-testing using saliva. In fact only 4 show up on this site and they are all in development, including Avacta.
Two are US-based (3M & Orasure) and the other is University of Lille.

Just to correct one figure mentioned twice earlier in this thread.
The award for transporting the “Innova” tests was $655k and not £600M!

The government awarded a contract today to fly supplies of LFDs in from Xiamen where the manufacturer is based.

Just in case people aren’t clear. This is to transport the Innova tests which are being manufactured by Xiamen Biotime. So it ties in with the Innova antigen test validation from August and the big order last month.

Blimey, if Riv’s a newbie not sure what that makes me.

Same here oogle.
It passes for two growth screens and also the “screen of screens”.

I sold my holding in Legal & General on Wednesday to top up my ODX shares, unaware at the time of the sell-off of ODX shares by L&G. Feel the money's better invested here.

Yes, 3 days by the issuer after receiving notice from the investor. The investor has 2 days to notify the issuer, making 5 days in all. The clock starts ticking from the day after the disposal which means you have just over a week to play with before the market must be notified.

And to add to that point, the info on the websites was correct on those days, but during the brief period L&G were disposing of shares. So all their notifications to ODX up to a certain date were accumulated into yesterday's RNS.
Might be more to come, but none of us can say at present.

My understanding is that it is a two-stage process, each stage having a different time limit by which info must be released.
So there's a period of a few trading days before the investor (L&G) needs to notify the issuer (ODX) and then another few days before the issuer needs to make that info public via an RNS. In total there could be more than 1 week between carrying out the sale and the RNS.